Active Ingredient History
Isoflurane (1-chloro-2, 2,2-trifluoroethyl difluoromethyl ether) a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Similar to many general anesthetics, the exact mechanism of the action has not been clearly delineated. Isoflurane reduces pain sensitivity (analgesia) and relaxes muscles. Isoflurane likely potentiates GABA-A and glycine receptor activity, which decreases motor function, inhibits receptor activity in the NMDA glutamate receptor subtypes and binds to glutamate receptors. Isoflurane is always administered in conjunction with air and/or pure oxygen. Often nitrous oxide is also used. Although its physical properties imply that anesthesia can be induced more rapidly than with halothane, its pungency can irritate the respiratory system, negating this theoretical advantage conferred by its physical properties. It is usually used to maintain a state of general anesthesia that has been induced with another drug, such as thiopentone or propofol. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Pain (approved 1979)
Alzheimer Disease (Phase 4)
Anesthesia (Phase 4)
Anesthesia, General (Phase 4)
Anesthetics, Inhalation (Phase 3)
Aortic Valve Insufficiency (Phase 3)
Breast Neoplasms (Phase 4)
Cardiovascular Diseases (Phase 4)
Cognition Disorders (Phase 4)
Colorectal Neoplasms (Phase 4)
Conscious Sedation (Phase 3)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 1)
Coronary Disease (Phase 4)
COVID-19 (Phase 3)
Delirium (Phase 4)
Depression (Phase 2)
Depressive Disorder, Major (Phase 2)
Depressive Disorder, Treatment-Resistant (Phase 2)
DNA Damage (Phase 4)
General Surgery (Phase 4)
Health (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 1)
Hematoma, Subdural, Acute (Phase 4)
Hemodynamics (Phase 4)
Hernia, Inguinal (Phase 3)
Hydrocephalus (Phase 3)
Hypertension, Pulmonary (Phase 4)
Hypotension (Phase 4)
Intensive Care Units, Pediatric (Phase 3)
Intestinal Pseudo-Obstruction (Phase 4)
Kidney Diseases (Phase 3)
Kidney Transplantation (Phase 2)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 4)
Melanoma (Phase 4)
Mitral Valve Insufficiency (Phase 3)
Myocardial Reperfusion Injury (Phase 4)
Myocardium (Phase 2/Phase 3)
Nausea (Phase 4)
Neoplasms (Phase 4)
Opioid-Related Disorders (Phase 2)
Pain, Postoperative (Phase 4)
Postoperative Complications (Phase 4)
Prostatic Neoplasms (Phase 4)
Renal Insufficiency (Phase 4)
Respiratory Distress Syndrome (Phase 2/Phase 3)
Shock, Septic (Phase 4)
Sleep (Phase 4)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 4)
Substance-Related Disorders (Phase 2)
Surgical Oncology (Phase 4)
Thoracic Surgery (Phase 4)
Ventilators, Mechanical (Phase 2/Phase 3)
Ventricular Dysfunction (Phase 4)
Vomiting (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue